Good morning. And welcome, everyone, to the Liquidia Corporation Second Quarter 2021 Financial Results and Corporate Update Conference Call. My name is Angie, and I’ll be your conference operator today. Currently, all participants are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions will be provided at that time for you to queue up for questions. [Operator Instructions] I would like to remind, everyone, that today’s conference call is being recorded. I would now like to hand the conference over to Jason Adair, Vice President, Corporate Development and Strategy. Please go ahead, sir.

Thank you, Angie. It’s my pleasure to welcome everyone to today’s conference call to discuss our second quarter financial results for 2021 and to provide a business update. Before we begin, I’d like to remind everyone that today’s call will contain forward-looking statements based on current expectations. Such statements may involve risks and uncertainties that may cause actual results to differ materially from these stated expectations. For further information on the company’s risk factors, please see Liquidia’s filings with the Securities and Exchange Commission at www.sec.gov or on Liquidia’s website at www.liquidia.com. I would now like to turn the call over to Chief Executive Officer, Damian deGoa for our prepared remarks, after which he will open up the call for your questions.

Thank you, Jason, and good morning, everyone. I am joined today by Mike Kaseta, our Chief Financial Officer and several members of our management, who may help address questions later in the call. My comments today will be brief and consistent with the release issued earlier today. What I can confidently say is that in seven months since I assume this role CEO we have delivered on every objective we set forth. We immediately address and increase the financial stability of the company, focusing it on value creating activity. We increase the value of our Treprostinil Injection product by securing the FDA clearance and launch of the RG 3ml Medication Cartridge that enables to deliver Treprostinil Injection by subcutaneous route of administration and more than doubles the addressable market for that product. We promptly resubmitted the NDA for LIQ861 now with a PDUFA day action in November. And we continue to engage in multiple work streams to defend our legal rights to provide choice and options for patients to receive Treprostinil therapy in a convenient, easy-to-use dry powder inhaler. Despite some minor setbacks along the way last year, we have shown perseverance. We were not deterred when restrictions imposed by other companies limited access to the cartridges needed by patients using the CADD-MS 3 pump. Instead, working with our manufacturing partner and through our litigation against Smiths Medical and United Therapeutics, we launched the RG 3ml Medication Cartridge earlier this year. We went above and beyond and solved the device problem in order to allow greater patient access to the Treprostinil Injection medication. It’s important to remember that our Treprostinil Injection is AP-rated and therapeutically equivalent to Remodulin, with the same active and inactive ingredients, same dosage strength, same dosage forms, the same Smiths Medical pumps, with the same services…

Thank you, Damian, and good morning, everyone. Our second quarter 2021 financial results can be found in the press release issued earlier today and our Form 10-Q filed with the SEC, both of which will be available on our website. To briefly summarize, we recognize revenue of $3.1 million for the second quarter 2021 related to our promotion agreement with Sandoz in support of Treprostinil Injection. The related costs of revenue during this quarter was $0.7 million. This compares to no revenue and no cost in the second quarter of 2020 since the acquisition of RareGen was not completed until November 2020. Research and Development expenses were $4.6 million for the second quarter, compared with $8.5 million for the second quarter of 2020, a decrease of $3.9 million or roughly 46%. This decrease primarily related to lower expenses from our 861 clinical program, and lower employee and consulting expenses. We continue to improve on general administrative expenses, recording $4.4 million for the second quarter of 2021, down from $5.2 million for the same quarter in the prior year. The decrease of $0.8 million or roughly 15% was primarily due to lower professional fees associated with corporate activities, and lower consulting and personnel expenses as a result of decreasing headcount year-over-year. These decreases were partially offset by an increase in legal fees related to our ongoing 861 related litigation. The net loss for the quarter was $6.5 million or $0.13 per basic and diluted share, compared to a net loss of $13.9 million or $0.49 per basic and diluted share for the second quarter of 2020. We ended the second quarter with cash of $67.9 million, compared to $65.3 million at the end of Q -- at the end of the year 2020. The increase in cash was a result of the refinance debt, a small equity raise of up $21.7 million in April and focused spending in the quarter. With a strong balance sheet we are well positioned to deliver on potential value creating events beyond regulatory approval and litigation. I would now like to turn the call back over to Damian.

Thanks, Mike. So, just as a summary, our near-term corporate goals are clear. One is to optimize Treprostinil Injection sales, two is to achieve tentative approval for 861, and three is to successfully resolve the Hatch-Waxman Litigation and launch 861 in 2022. At this time, I would like to ask our Operator to facilitate any questions that you may have.

[Operator Instructions] Your first question comes from the line of Kambiz Yazdi with Jefferies.

Good morning, Damian and team. What’s your split this quarter between IV and subcutaneous generic Treprostinil sales? Could you -- there is a three parter, sorry, can you please provide us any additional details on the claims construction? And then my third and final question is, you mentioned last call that 861 may be able to be approved in ILD without any additional studies. Can you describe to us what regulatory steps are needed to achieve that and if there’s any kind of data exclusivity there? Thank you.

Yeah. Thanks, Kambiz. I’ll try to parse these out. I don’t know if Rusty if you’re available to talk about the claims construction on the second one. In regards to the IV versus subcu sale split, we aren’t disclosing that at this time. I do want to say, though, that the launch has gone really well. The uptake and patient conversions and new starts into the generic Treprostinil Injection is going really well. If you -- we basically launched in June of the quarter, so we only had one month of the uptick. But there’s both lift in subcu and in the IV side of the market, as we expect it to be. We’re also seeing really good payer engagement and payer interest in moving the utilization of generic to a much higher level. So all those are positive and we’ll be able to give you more insights after next quarter. Rusty, are you on to talk about the claims construction?

I am. Thanks, Damian. With respect to the claim construction hearing, there were five terms that were an issue in the hearing. The judges ruled on three of those terms, with two terms still under consideration by the court. Of the three terms that were construed, two terms were given their plain and ordinary meaning, and one term, the judge ruled in our favor as to the construction of that term. Thank you.

Thanks, Rusty. And Kambiz, for the last question in relation to the ILD indication, it is our intention to go after that indication. United Therapeutics in the Tyvaso nebulize product was granted a three-year data exclusivity that goes until March of 2024. And so we’ll be obviously looking to try to add that indication once that exclusivity is expired.

Great. Thanks, Damian. I really appreciate the answers.

Sure.

[Operator Instructions] Your next question comes from the line of Serge Belanger with Needham.

Hey. Good morning. Thanks for taking my questions. I have a couple on the generic Remodulin product. You mentioned the subcu product kind of doubles the market opportunity. Can you talk about the ongoing work with payers and whether patient -- all patients currently have access to the subcu product or it will come with additional contracting?

Yes. So right now there’s an opportunity for all patients to be able to use the generic Treprostinil both on the IV side and the subcu side. There’s a lot of payer interest, and frankly, some payer mandates that are have been instituted by the payers. But there’s no required additional contracting in order for patients to be able to use the generic, if that’s what your question was.

Okay. And I think in the past, you’ve talked about the profit split would Sandoz kind of moving around -- moving downwards as you reach a certain sales threshold? Have you reached that threshold or when do you expect to reach it?

Yeah. We haven’t met it yet. But we anticipate that it’ll be either in end of Q3 or Q -- or the beginning of Q4 that we will likely trigger that change.

Got it. All right. Thank you.

Yeah.

At this time, there are no further questions. I would now like to turn the floor back to management for any additional or closing remarks.

Thank you. We appreciate, everyone, listening to our Q2 call. We’re in execution mode and I think we’re doing a good job of blocking and tackling, and doing what we need to do to continue to advance the company and the programs that we have. So thank, everyone, for the time and be well.

Thank you for participating in today’s conference call. You may now disconnect your lines at this time.